Want to see IL:NRGN full AI Analyst Report?
NRGN Stock Chart & Stats
139.30
0.03(0.96%)
At close: 4:00 PM EST
139.30
0.03(0.96%)
Day’s Range― - ―
52-Week Range100.20 - 305.90
Previous CloseN/A
Volume1.26K
Average Volume (3M)6.80K
Market Cap
₪13.55M
Enterprise Value5.76M
Total Cash (Recent Filing)₪3.18M
Total Debt (Recent Filing)₪145.02K
Price to Earnings (P/E)―
Beta0.58
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,327,785
10 Day Avg. Volume5,292
30 Day Avg. Volume6,796
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.94
Price to Sales (P/S)2.64
P/FCF Ratio116.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp 2025 revenue rebound indicates renewed demand for Nrgene’s genomics software and services after a prolonged contraction. If the improved trajectory persists, a larger revenue base can support operating leverage, broaden customer reach, and provide greater resources for product development and commercial expansion.
Gross Margin ImprovementThe material gross-margin improvement suggests better economics on the company’s software and genomics activities, whether through stronger pricing, mix, or delivery efficiency. Higher gross profit per unit of revenue creates more capacity to fund research, sales, and support while improving the path toward sustainable profitability.
Conservative LeverageVery low debt relative to equity gives Nrgene financial flexibility while it works to scale its genomics platform and convert recent operating improvements into earnings. Limited leverage reduces interest burden and refinancing exposure, allowing more cash resources to remain available for investment and business development.
Bears Say
Persistent Operating LossesThe company’s substantial net and operating losses show that the revenue rebound and better gross margin have not yet produced a viable earnings model. Continued negative EBIT can require additional funding, constrain investment choices, and make profitability dependent on further scale or major cost improvements.
Unproven Free-cash-flow DurabilityAlthough operating cash flow turned positive, free cash flow remained modest and declined sharply versus the prior year. Small, volatile cash generation provides limited evidence that the business can self-fund consistently, leaving durability of cash conversion uncertain as the company pursues growth.
Negative Shareholder ReturnsNegative return on equity reflects that capital is currently supporting losses rather than generating shareholder value. The prior period of negative equity also demonstrates balance-sheet sensitivity to sustained losses, meaning continued underperformance could weaken financial resilience even though current leverage is low.
NRGN FAQ
What was NRGENE TECHNOLOGIES LTD’s price range in the past 12 months?
NRGENE TECHNOLOGIES LTD lowest stock price was 100.20 and its highest was 305.90 in the past 12 months.
What is NRGENE TECHNOLOGIES LTD’s market cap?
NRGENE TECHNOLOGIES LTD’s market cap is ₪13.55M.
When is NRGENE TECHNOLOGIES LTD’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NRGENE TECHNOLOGIES LTD’s earnings last quarter?
Currently, no data Available
Is NRGENE TECHNOLOGIES LTD overvalued?
According to Wall Street analysts NRGENE TECHNOLOGIES LTD’s price is currently Overvalued.
Does NRGENE TECHNOLOGIES LTD pay dividends?
NRGENE TECHNOLOGIES LTD does not currently pay dividends.
What is NRGENE TECHNOLOGIES LTD’s EPS estimate?
NRGENE TECHNOLOGIES LTD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NRGENE TECHNOLOGIES LTD have?
NRGENE TECHNOLOGIES LTD has 13,327,785 shares outstanding.
What happened to NRGENE TECHNOLOGIES LTD’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NRGENE TECHNOLOGIES LTD?
Currently, no hedge funds are holding shares in IL:NRGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NRGENE TECHNOLOGIES LTD
NRGene Technologies Ltd is an AI-powered genomics firm that designs sophisticated computational tools and advanced algorithms, serving clients globally across North America, Europe, the Middle East, Africa, and Asia Pacific. The company provides specialized software applications and complete, ready-to-use solutions for various sectors, including agricultural breeding, food technology, academia, research institutions, and agribiotech enterprises. Additionally, NRGene develops custom genetic panels tailored for a broad range of plants, from staple crops like wheat, canola, corn, soybeans, and maize to cannabis. Established in 2009, its headquarters are located in Ness Ziona, Israel.